Oluyemi Okupe Sells 7,163 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 7,163 shares of the firm’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $36.49, for a total value of $261,377.87. Following the transaction, the chief financial officer directly owned 284,321 shares in the company, valued at approximately $10,374,873.29. This represents a 2.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, June 22nd, Oluyemi Okupe sold 18,197 shares of Hims & Hers Health stock. The shares were sold at an average price of $34.03, for a total transaction of $619,243.91.
• On Monday, May 18th, Oluyemi Okupe sold 7,950 shares of Hims & Hers Health stock. The stock was sold at an average price of $23.64, for a total transaction of $187,938.00.
• On Monday, April 20th, Oluyemi Okupe sold 19,645 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.96, for a total value of $588,564.20.
• On Thursday, April 16th, Oluyemi Okupe sold 36,922 shares of Hims & Hers Health stock. The shares were sold at an average price of $25.90, for a total value of $956,279.80.
• On Friday, April 17th, Oluyemi Okupe sold 18,005 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.83, for a total transaction of $501,079.15.

Hims & Hers Health Stock Performance

HIMS opened at $36.04 on Thursday. The stock’s 50 day simple moving average is $29.05 and its 200 day simple moving average is $26.34. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.56. The stock has a market cap of $8.34 billion, a P/E ratio of -400.44, a P/E/G ratio of 101.79 and a beta of 2.35. Hims & Hers Health, Inc. has a 1-year low of $13.74 and a 1-year high of $70.43.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The firm had revenue of $608.10 million during the quarter, compared to analysts’ expectations of $616.84 million. Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The company’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.20 EPS. As a group, equities analysts anticipate that Hims & Hers Health, Inc. will post 0.03 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on HIMS. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $25.00 price target on shares of Hims & Hers Health in a report on Tuesday, May 5th. BTIG Research reiterated a “neutral” rating on shares of Hims & Hers Health in a report on Tuesday, May 12th. Bank of America raised their price objective on Hims & Hers Health from $25.00 to $36.00 and gave the stock a “neutral” rating in a report on Wednesday, July 1st. Leerink Partners lifted their price objective on Hims & Hers Health from $17.50 to $25.00 and gave the company a “market perform” rating in a research report on Monday, March 16th. Finally, JPMorgan Chase & Co. reduced their target price on Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Four research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $30.63.

Hedge Funds Weigh In On Hims & Hers Health

A number of large investors have recently modified their holdings of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Hims & Hers Health by 23.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock worth $12,373,000 after purchasing an additional 78,543 shares in the last quarter. Geneos Wealth Management Inc. purchased a new stake in Hims & Hers Health during the first quarter worth approximately $30,000. EverSource Wealth Advisors LLC increased its position in shares of Hims & Hers Health by 273.7% in the second quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock worth $47,000 after acquiring an additional 687 shares in the last quarter. Amundi increased its position in shares of Hims & Hers Health by 5.3% in the second quarter. Amundi now owns 10,296 shares of the company’s stock worth $489,000 after acquiring an additional 522 shares in the last quarter. Finally, California Public Employees Retirement System raised its stake in shares of Hims & Hers Health by 9.5% in the 2nd quarter. California Public Employees Retirement System now owns 338,620 shares of the company’s stock valued at $16,880,000 after acquiring an additional 29,471 shares during the period. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.